Annual CFI
-$11.68 M
-$175.31 M-107.14%
31 December 2023
Summary:
Ligand Pharmaceuticals Incorporated annual cash flow from investing activities is currently -$11.68 million, with the most recent change of -$175.31 million (-107.14%) on 31 December 2023. During the last 3 years, it has fallen by -$243.33 million (-105.04%). LGND annual CFI is now -102.50% below its all-time high of $466.92 million, reached on 31 December 2019.LGND Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFI
-$46.51 M
+$8.25 M+15.07%
30 September 2024
Summary:
Ligand Pharmaceuticals Incorporated quarterly cash flow from investing activities is currently -$46.51 million, with the most recent change of +$8.25 million (+15.07%) on 30 September 2024. Over the past year, it has dropped by -$27.00 million (-138.46%). LGND quarterly CFI is now -114.01% below its all-time high of $332.07 million, reached on 30 September 2020.LGND Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFI
-$115.33 M
-$27.00 M-30.57%
30 September 2024
Summary:
Ligand Pharmaceuticals Incorporated TTM cash flow from investing activities is currently -$115.33 million, with the most recent change of -$27.00 million (-30.57%) on 30 September 2024. Over the past year, it has dropped by -$106.64 million (-1228.32%). LGND TTM CFI is now -114.32% below its all-time high of $805.40 million, reached on 30 September 2019.LGND TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LGND Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -107.1% | -138.5% | -1228.3% |
| 3 y3 years | -105.0% | -155.3% | +63.5% |
| 5 y5 years | +97.2% | -127.4% | -114.3% |
LGND Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -105.0% | at low | -140.8% | +15.1% | -170.5% | +63.5% |
| 5 y | 5 years | -102.5% | +97.2% | -114.0% | +87.8% | -114.3% | +63.5% |
| alltime | all time | -102.5% | +97.2% | -114.0% | +92.1% | -114.3% | +84.3% |
Ligand Pharmaceuticals Incorporated Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$46.51 M(-15.1%) | -$115.33 M(+30.6%) |
| June 2024 | - | -$54.76 M(+1350.6%) | -$88.32 M(+239.6%) |
| Mar 2024 | - | -$3.77 M(-63.3%) | -$26.01 M(+122.6%) |
| Dec 2023 | -$11.68 M(-107.1%) | -$10.28 M(-47.3%) | -$11.68 M(+34.6%) |
| Sept 2023 | - | -$19.50 M(-358.1%) | -$8.68 M(-128.9%) |
| June 2023 | - | $7.56 M(-28.4%) | $30.00 M(-50.2%) |
| Mar 2023 | - | $10.55 M(-244.8%) | $60.29 M(-63.2%) |
| Dec 2022 | $163.62 M(+436.1%) | -$7.28 M(-138.0%) | $163.62 M(+21.0%) |
| Sept 2022 | - | $19.18 M(-49.3%) | $135.19 M(+38.2%) |
| June 2022 | - | $37.85 M(-66.8%) | $97.80 M(+23.3%) |
| Mar 2022 | - | $113.88 M(-418.9%) | $79.29 M(+159.8%) |
| Dec 2021 | $30.52 M(-86.8%) | -$35.71 M(+96.0%) | $30.52 M(-109.7%) |
| Sept 2021 | - | -$18.22 M(-194.2%) | -$315.97 M(-1020.6%) |
| June 2021 | - | $19.34 M(-70.3%) | $34.32 M(-391.5%) |
| Mar 2021 | - | $65.11 M(-117.0%) | -$11.77 M(-105.1%) |
| Dec 2020 | $231.65 M(-50.4%) | -$382.20 M(-215.1%) | $231.65 M(-57.9%) |
| Sept 2020 | - | $332.07 M(-1341.1%) | $550.67 M(+41.9%) |
| June 2020 | - | -$26.76 M(-108.7%) | $388.12 M(-43.0%) |
| Mar 2020 | - | $308.54 M(-588.4%) | $680.68 M(+45.8%) |
| Dec 2019 | $466.92 M(-210.3%) | -$63.18 M(-137.3%) | $466.92 M(-42.0%) |
| Sept 2019 | - | $169.52 M(-36.2%) | $805.40 M(+44.4%) |
| June 2019 | - | $265.80 M(+180.5%) | $557.63 M(-289.1%) |
| Mar 2019 | - | $94.78 M(-65.6%) | -$294.91 M(-30.3%) |
| Dec 2018 | -$423.27 M(+434.6%) | $275.30 M(-451.8%) | -$423.27 M(-42.4%) |
| Sept 2018 | - | -$78.25 M(-86.7%) | -$734.75 M(+3.0%) |
| June 2018 | - | -$586.74 M(+1647.2%) | -$713.03 M(+718.7%) |
| Mar 2018 | - | -$33.58 M(-7.2%) | -$87.09 M(+10.0%) |
| Dec 2017 | -$79.18 M(-41.1%) | -$36.17 M(-36.0%) | -$79.18 M(-34.5%) |
| Sept 2017 | - | -$56.54 M(-244.2%) | -$120.95 M(+103.8%) |
| June 2017 | - | $39.20 M(-252.7%) | -$59.34 M(-26.1%) |
| Mar 2017 | - | -$25.67 M(-67.1%) | -$80.32 M(-40.2%) |
| Dec 2016 | -$134.41 M(+19.1%) | -$77.95 M(-1635.1%) | -$134.41 M(+97.8%) |
| Sept 2016 | - | $5.08 M(-72.1%) | -$67.94 M(-31.6%) |
| June 2016 | - | $18.22 M(-122.8%) | -$99.39 M(-47.6%) |
| Mar 2016 | - | -$79.76 M(+595.0%) | -$189.82 M(+68.2%) |
| Dec 2015 | -$112.86 M(+5467.9%) | -$11.48 M(-56.5%) | -$112.86 M(+9.5%) |
| Sept 2015 | - | -$26.36 M(-63.5%) | -$103.10 M(+34.5%) |
| June 2015 | - | -$72.22 M(+2482.2%) | -$76.66 M(+1903.6%) |
| Mar 2015 | - | -$2.80 M(+63.5%) | -$3.83 M(+88.8%) |
| Dec 2014 | -$2.03 M(-59.2%) | -$1.71 M(-2443.8%) | -$2.03 M(+53.7%) |
| Sept 2014 | - | $73.00 K(-88.0%) | -$1.32 M(-19.4%) |
| June 2014 | - | $609.00 K(-161.0%) | -$1.64 M(-72.4%) |
| Mar 2014 | - | -$998.00 K(-0.5%) | -$5.94 M(+19.4%) |
| Dec 2013 | -$4.97 M(-493.8%) | -$1.00 M(+309.4%) | -$4.97 M(+23.0%) |
| Sept 2013 | - | -$245.00 K(-93.4%) | -$4.04 M(-34.4%) |
| June 2013 | - | -$3.69 M(>+9900.0%) | -$6.17 M(+127.0%) |
| Mar 2013 | - | -$34.00 K(-52.8%) | -$2.72 M(-315.0%) |
| Dec 2012 | $1.26 M(-105.0%) | -$72.00 K(-97.0%) | $1.26 M(-233.8%) |
| Sept 2012 | - | -$2.37 M(+878.5%) | -$944.00 K(-173.3%) |
| June 2012 | - | -$242.00 K(-106.1%) | $1.29 M(-35.1%) |
| Mar 2012 | - | $3.94 M(-273.1%) | $1.98 M(-107.9%) |
| Dec 2011 | -$25.13 M(-272.8%) | -$2.28 M(+1563.5%) | -$25.13 M(+15.2%) |
| Sept 2011 | - | -$137.00 K(-130.2%) | -$21.82 M(+62.7%) |
| June 2011 | - | $453.00 K(-102.0%) | -$13.41 M(+7.2%) |
| Mar 2011 | - | -$23.17 M(-2353.8%) | -$12.51 M(-186.0%) |
| Dec 2010 | $14.54 M(-41.3%) | $1.03 M(-87.6%) | $14.54 M(-43.2%) |
| Sept 2010 | - | $8.28 M(+510.3%) | $25.59 M(-15.7%) |
| June 2010 | - | $1.36 M(-65.1%) | $30.36 M(+22.6%) |
| Mar 2010 | - | $3.88 M(-67.9%) | $24.77 M(+0.0%) |
| Dec 2009 | $24.77 M | $12.07 M(-7.5%) | $24.77 M(+4.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2009 | - | $13.05 M(-408.5%) | $23.65 M(+237.7%) |
| June 2009 | - | -$4.23 M(-209.2%) | $7.00 M(-147.4%) |
| Mar 2009 | - | $3.87 M(-64.7%) | -$14.77 M(-39.5%) |
| Dec 2008 | -$24.42 M(-107.1%) | $10.96 M(-404.7%) | -$24.42 M(+68.4%) |
| Sept 2008 | - | -$3.60 M(-86.2%) | -$14.51 M(-29.4%) |
| June 2008 | - | -$26.01 M(+350.2%) | -$20.56 M(-274.6%) |
| Mar 2008 | - | -$5.78 M(-127.7%) | $11.78 M(-96.6%) |
| Dec 2007 | $343.84 M(+74.7%) | $20.88 M(-316.4%) | $343.84 M(-34.2%) |
| Sept 2007 | - | -$9.65 M(-252.6%) | $522.70 M(-1.1%) |
| June 2007 | - | $6.32 M(-98.1%) | $528.61 M(+1.6%) |
| Mar 2007 | - | $326.28 M(+63.3%) | $520.15 M(+164.2%) |
| Dec 2006 | $196.87 M(-683.9%) | $199.75 M(-5435.1%) | $196.87 M(+8692.5%) |
| Sept 2006 | - | -$3.74 M(+75.6%) | $2.24 M(-86.9%) |
| June 2006 | - | -$2.13 M(-171.2%) | $17.04 M(+92.5%) |
| Mar 2006 | - | $3.00 M(-41.5%) | $8.85 M(-126.3%) |
| Dec 2005 | -$33.72 M(-271.9%) | $5.12 M(-53.7%) | -$33.72 M(+55.5%) |
| Sept 2005 | - | $11.05 M(-207.1%) | -$21.68 M(-9.6%) |
| June 2005 | - | -$10.32 M(-73.9%) | -$23.98 M(-12.7%) |
| Mar 2005 | - | -$39.58 M(-330.6%) | -$27.47 M(-240.1%) |
| Dec 2004 | $19.61 M(-237.8%) | $17.16 M(+96.0%) | $19.61 M(-231.3%) |
| Sept 2004 | - | $8.76 M(-163.4%) | -$14.93 M(-27.6%) |
| June 2004 | - | -$13.82 M(-284.0%) | -$20.62 M(+518.8%) |
| Mar 2004 | - | $7.51 M(-143.2%) | -$3.33 M(-76.6%) |
| Dec 2003 | -$14.23 M(-88.5%) | -$17.38 M(-666.0%) | -$14.23 M(-87.9%) |
| Sept 2003 | - | $3.07 M(-11.5%) | -$118.00 M(-2.8%) |
| June 2003 | - | $3.47 M(-202.3%) | -$121.42 M(-1.8%) |
| Mar 2003 | - | -$3.39 M(-97.2%) | -$123.58 M(-0.4%) |
| Dec 2002 | -$124.12 M(+2875.0%) | -$121.15 M(>+9900.0%) | -$124.12 M(-9560.3%) |
| Sept 2002 | - | -$342.00 K(-126.3%) | $1.31 M(-141.8%) |
| June 2002 | - | $1.30 M(-133.1%) | -$3.14 M(+27.0%) |
| Mar 2002 | - | -$3.93 M(-191.8%) | -$2.47 M(-40.8%) |
| Dec 2001 | -$4.17 M(-133.3%) | $4.28 M(-189.3%) | -$4.17 M(+22.1%) |
| Sept 2001 | - | -$4.79 M(-343.4%) | -$3.42 M(-181.8%) |
| June 2001 | - | $1.97 M(-135.0%) | $4.18 M(+55.9%) |
| Mar 2001 | - | -$5.63 M(-211.8%) | $2.68 M(-78.6%) |
| Dec 2000 | $12.51 M(-148.5%) | $5.04 M(+79.7%) | $12.51 M(+120.4%) |
| Sept 2000 | - | $2.80 M(+494.9%) | $5.68 M(-120.3%) |
| June 2000 | - | $471.00 K(-88.8%) | -$27.93 M(+26.4%) |
| Mar 2000 | - | $4.20 M(-333.5%) | -$22.10 M(-14.4%) |
| Dec 1999 | -$25.80 M(-9.8%) | -$1.80 M(-94.2%) | -$25.80 M(-44.6%) |
| Sept 1999 | - | -$30.80 M(-588.9%) | -$46.60 M(+301.7%) |
| June 1999 | - | $6.30 M(+1160.0%) | -$11.60 M(-1.7%) |
| Mar 1999 | - | $500.00 K(-102.2%) | -$11.80 M(-58.7%) |
| Dec 1998 | -$28.60 M(-765.1%) | -$22.60 M(-638.1%) | -$28.60 M(+853.3%) |
| Sept 1998 | - | $4.20 M(-31.1%) | -$3.00 M(+50.0%) |
| June 1998 | - | $6.10 M(-137.4%) | -$2.00 M(-60.0%) |
| Mar 1998 | - | -$16.30 M(-643.3%) | -$5.00 M(-216.3%) |
| Dec 1997 | $4.30 M(-42.7%) | $3.00 M(-42.3%) | $4.30 M(-175.4%) |
| Sept 1997 | - | $5.20 M(+67.7%) | -$5.70 M(+32.6%) |
| June 1997 | - | $3.10 M(-144.3%) | -$4.30 M(+2.4%) |
| Mar 1997 | - | -$7.00 M(0.0%) | -$4.20 M(-156.0%) |
| Dec 1996 | $7.50 M(-73.8%) | -$7.00 M(-206.1%) | $7.50 M(-48.3%) |
| Sept 1996 | - | $6.60 M(+106.3%) | $14.50 M(+83.5%) |
| June 1996 | - | $3.20 M(-31.9%) | $7.90 M(+68.1%) |
| Mar 1996 | - | $4.70 M(+20.5%) | $4.70 M(+213.3%) |
| Dec 1995 | $28.60 M(+2500.0%) | - | - |
| Mar 1995 | - | $3.90 M(>+9900.0%) | $1.50 M(+36.4%) |
| Dec 1994 | $1.10 M | $0.00(-100.0%) | $1.10 M(0.0%) |
| Sept 1994 | - | -$5.60 M(-275.0%) | $1.10 M(-83.6%) |
| June 1994 | - | $3.20 M(-8.6%) | $6.70 M(+91.4%) |
| Mar 1994 | - | $3.50 M | $3.50 M |
FAQ
- What is Ligand Pharmaceuticals Incorporated annual cash flow from investing activities?
- What is the all time high annual CFI for Ligand Pharmaceuticals Incorporated?
- What is Ligand Pharmaceuticals Incorporated annual CFI year-on-year change?
- What is Ligand Pharmaceuticals Incorporated quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Ligand Pharmaceuticals Incorporated?
- What is Ligand Pharmaceuticals Incorporated quarterly CFI year-on-year change?
- What is Ligand Pharmaceuticals Incorporated TTM cash flow from investing activities?
- What is the all time high TTM CFI for Ligand Pharmaceuticals Incorporated?
- What is Ligand Pharmaceuticals Incorporated TTM CFI year-on-year change?
What is Ligand Pharmaceuticals Incorporated annual cash flow from investing activities?
The current annual CFI of LGND is -$11.68 M
What is the all time high annual CFI for Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals Incorporated all-time high annual cash flow from investing activities is $466.92 M
What is Ligand Pharmaceuticals Incorporated annual CFI year-on-year change?
Over the past year, LGND annual cash flow from investing activities has changed by -$175.31 M (-107.14%)
What is Ligand Pharmaceuticals Incorporated quarterly cash flow from investing activities?
The current quarterly CFI of LGND is -$46.51 M
What is the all time high quarterly CFI for Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals Incorporated all-time high quarterly cash flow from investing activities is $332.07 M
What is Ligand Pharmaceuticals Incorporated quarterly CFI year-on-year change?
Over the past year, LGND quarterly cash flow from investing activities has changed by -$27.00 M (-138.46%)
What is Ligand Pharmaceuticals Incorporated TTM cash flow from investing activities?
The current TTM CFI of LGND is -$115.33 M
What is the all time high TTM CFI for Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals Incorporated all-time high TTM cash flow from investing activities is $805.40 M
What is Ligand Pharmaceuticals Incorporated TTM CFI year-on-year change?
Over the past year, LGND TTM cash flow from investing activities has changed by -$106.64 M (-1228.32%)